Merck & Co Inc

MRK: XNYS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
FB%LOCK|yV#LOCK|X&^C#k#

Moderna and Merck: Intismeran's Positive Phase 3 Readout Confirms mRNA Potential in Oncology

In a Phase 3 study, individualized neoantigen therapy intismeran improved recurrence-free survival and distant metastasis-free survival in melanoma patients when combined with Keytruda, relative to Keytruda alone. Moderna shares rose nearly 150% and Merck rose over 10% intraday on Aug. 19.

Sponsor Center